Digital diagnostics developer EDX Medical Group and precision medicine company Caris Life Sciences have signed a distribution agreement for Caris' molecular profiling services.
Under the terms of the agreement, EDX Medical and Caris will collaborate on a mutually exclusive basis for a minimum of three years to distribute Caris' solid tumor and liquid biopsy molecular profiling services, as well as artificial intelligence (AI) solutions for clinical and research use in the U.K. and Nordic countries (Sweden, Norway, Denmark, and Finland), with additional regions and products to follow in the future, according to a statement from the companies.
"EDX Medical and Caris are both pioneer companies unified by their focus on providing doctors with access to the best biological information possible from valuable human samples," Dr. Mike Hudson, CEO of EDX Medical, said. "We are proud to have been selected by Caris to play a key role in jointly bringing these incredibly useful cancer tumor profiling services to the U.K. and key areas of Europe."
Financial and other terms of the agreement were not disclosed.
